Zentalis Pharmaceuticals (NASDAQ:ZNTL) Announces Earnings Results

Zentalis Pharmaceuticals (NASDAQ:ZNTL) released its earnings results on Tuesday. The company reported ($0.67) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.67), Zacks reports.

Zentalis Pharmaceuticals Stock Performance

Zentalis Pharmaceuticals stock opened at $1.19 on Thursday. Zentalis Pharmaceuticals has a fifty-two week low of $1.01 and a fifty-two week high of $13.00. The firm has a 50 day moving average price of $1.46 and a 200 day moving average price of $2.35. The company has a market capitalization of $85.62 million, a PE ratio of -0.48 and a beta of 1.81.

Insider Activity at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, Director Scott Dunseth Myers purchased 21,000 shares of the company’s stock in a transaction on Wednesday, April 30th. The stock was acquired at an average price of $1.40 per share, for a total transaction of $29,400.00. Following the completion of the purchase, the director now directly owns 281,192 shares in the company, valued at approximately $393,668.80. The trade was a 8.07% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.90% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research analysts have weighed in on ZNTL shares. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Zentalis Pharmaceuticals in a research note on Thursday. Wedbush reaffirmed a “neutral” rating and set a $4.00 price target on shares of Zentalis Pharmaceuticals in a research report on Friday, March 28th. Wells Fargo & Company reduced their price target on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 30th. Finally, UBS Group reduced their price target on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $8.24.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.